

INVITATION

(conducted according to the article 211 par. 4 of law 4548/218)

**OF THE SHAREHOLDERS OF THE REGISTERED COMPANY MEDICON HELLAS S.A ,
“AYTOMATIC ANALYSERS - PRIVATE DIAGNOSTIC REAGENTS AND PRIVATE
DIAGNOSTIC LABORATORIES MEDICON HELLAS S.A”**

GEMI No: 41440100

(PR. MAE No. 16439/6/B/88/24)

TO THE EXTRAORDINARY GENERAL MEETING ON 16TH OF DECEMBER 2022

After the decision from the Board of Directors on 23.21.2022 and according to the company's statute, the shareholders are invited to an Extraordinary General Meeting, that will be held on the 16th of December 2022, on Friday at 13:00 p.m at the company's premises (Melitona 5-7, Gerakas Attikis, 1st floor), to discuss and decide on the following:

- 1) Offsetting of reserves exempt from taxation and reserves from income taxed to amortize losses of equal amounts from previous years and providing relevant authorizations to the Board of Directors.
- 2) Amendment of article 3 of the company's articles of association with the aim of expanding the corporate purpose and codifying it.

According to the article 121 par. 4, 124 and 128 of law 4548/2018 as it is valid until today, the company informs the shareholders on the following:

A. THE RIGHT TO VOTE AND PARTICIPATE

Each share entitles one (1) vote. Anyone appearing as a shareholder in the records of the Securities Exchange System (S.A.T.) managed by the "HELLENIC STOCK EXCHANGE S.A." is entitled to participate in the Extraordinary General Meeting. (E.X.A.E.), in which the securities (shares) of the Company are kept. The status of the shareholder must exist on the **11th.12.2022 (record date)**, i.e. at the beginning of the fifth (5th) day

before the day of the meeting of the Extraordinary General Meeting on the 16th.12.2022. The proof of shareholder status can be done by any legal means and in any case based on information received by the Company from the central securities depository, if it provides registry services or through the participating and registered intermediaries in the central securities depository in any other case. In relation to the Company, it is considered that only anyone who holds the status of shareholder on the respective registration date has the right to participate and vote in the Extraordinary General Meeting. It is noted that the exercise of said rights (participation and voting) does not require the freezing of the beneficiary's shares nor the observance of any other similar procedure, which limits the possibility of selling and transferring them during the period of time between the date of registration and the date of the Extraordinary General Assembly.

B. THE RIGHTS OF THE MINORITY OF SHAREHOLDERS

(a) With an application from the shareholders that represent the one twentieth (1/20) of the shared capital, the company's Board of Directors is obligated to register at the daily agenda of the Extraordinary General Meeting any additional subjects, if the relevant application arrives at the Board of Directors until the **1st.12.2022, which is at least fifteen (15) days prior to the date of Extraordinary General Meeting**. The application for the registry of the additional subjects for the daily agenda is accompanied by a justification or by a decision plan that has to be approved at the Extraordinary General Meeting, and if the revised daily agenda is being published in any way like the previous daily agenda, on the **3rd.12.2022, which is at least thirteen (13) days prior the date of the Extraordinary General Meeting** and at the same time, it is published at the company's website, to which the shareholders have access, along with the justification or the decision plan that has been submitted by the shareholders, according to article 123 par 4 of law 4548/2018.

(b) With an application from the shareholders that represent the one twentieth (1/20) of the shared capital, the company's Board of Directors sets at the shareholder's disposal based on article 123 par.3 of law 4548/2018, the latest until the **10th.12.2022, which is at least six (6) days prior to the date of the Extraordinary**

General Meeting, the plans of decision making for the subjects that are included in the initial or the revised daily agenda, if the relevant application arrives at the Board of Directors until the **9th.12.2022, which is seven (7) days prior to the date of the Extraordinary General Meeting.**

(c) After the application from any shareholder that is submitted at the company, before the last **five (5) days prior to the date of the Extraordinary General Meeting**, the Board of Directors is obligated to provide at the Extraordinary General Meeting, the requested information to the extent that they are relevant to the subjects under discussion on the daily agenda. There is no obligation to provide information that is already publicly available to the company's website, especially if this information is in the form of questions and answers. Furthermore, with an application from the shareholders that represent the one twentieth (1/20) of the shared capital, the Board of Directors is obligated to announce at the Extraordinary General Meeting, the amounts that they were paid over the last two years at every Board member or at the managers of the company, as well as any provision to these members due to any cause or contract of the company towards them. For all the aforementioned cases, the Board of Directors can deny the provision of information due to substantial reason that will be written on the agenda.

(d) If an application from the shareholders that represent the one tenth (1/10) of the shared capital, is submitted to the company at least **five (5) days prior to the Extraordinary General Meeting**, the Board of Directors is obligated to provide at the Extraordinary General Meeting, information about the course of corporate matters as well as the financial state of the company. For all the aforementioned cases, the Board of Directors can deny the provision of information due to substantial reason that will be written on the agenda.

(e) With an application from the shareholders that represent the one twentieth (1/20) of the shared capital, the voting on a subject or on some subjects on the daily agenda, are conducted with transparent voting.

For all the aforementioned cases, the shareholders that have proceeded with an application, they have to prove their shareholder's capacity, apart from the first case of paragraph 6 of article 141 of law 4548/2018, the number of shares they own at the time they proceed with the application. The proof of the shareholder's capacity can

be done by using any legal means and with the update that the company is receiving from the central securities repository or through the participants or registered intermediaries at the central securities repository.

C. THE PROCESS FOR THE VOTING RIGHT THROUGH A REPRESENTATIVE

The shareholder participates in the Extraordinary General Meeting and votes either in person or through a proxy. Each shareholder may appoint up to three (3) representatives. Legal entities participate in the General Meeting by appointing up to three (3) natural persons as their representatives. However, if the shareholder owns shares of the Company, which appear in more than one securities account, this limitation does not prevent such shareholder from appointing different proxies for the shares that appear in each securities account in relation to the General Meeting. A proxy acting for several shareholders may vote differently for each shareholder. A representative that represents more than one shareholder, can vote differently for each shareholder.

The representative is obligated to inform the company, prior to the beginning of the Extraordinary General Meeting, of any specific fact that can be useful for the shareholders to assess the risk of serving other interests to the ones of the shareholder they represent. From this paragraph, a conflict of interest may arise especially if the representative:

- (a) is a shareholder that exercises the control of the company, or is any other legal entity whom is being controlled by this shareholder,
- (b) is a member of the Board of Directors or in general of the management of the Company or of a controlling shareholder of the Company or of another legal person or entity controlled by a controlling shareholder of the Company,
- (c) is an employee or an auditor of the company or the shareholder that exercises the control of the company or any other legal entity that is being controlled by the shareholder whom has the company's control.

(d) is a spouse or a first degree relative with one of the cases mentioned in (a) through (c).

The appointment, the revoke and the replacement of the shareholders' representative should be made in writing and submitted to the company, at least forty-eight (48) before the date of the Extraordinary General Meeting.

The Company has made available on its website (www.mediconsa.com) the form to appoint a representative. The aforementioned form is submitted completed and signed by the shareholder to the Company's Shareholder Service Department at Geraka Attica, 5-7 Melitona Street, or sent by fax to fax 210-6612666 at least forty-eight (48) hours before the date of the Extraordinary General Meeting Meeting.

It is the shareholder's responsibility to confirm the application has been received and processed by calling during working hours on the number 210 – 6606129,

D. AVAILABLE DOCUMENTS

The full script of the decisions and of any documents that are provided in article 123 par.4 of law 4548/2018 will be available in printed documents at the company's premises (Gerakas Attikis, Melitona 5-7).

E. AVAILABLE INFORMATION

The information from par.3 and 4 of article 123 of law 4548/2018 will be available in digital form at the company's webpage www.mediconsa.com.

Gerakas Attikis, 23 November 2022

Upon order form the Board of Directors

THE PRESIDENT OF B.O.D AND C.E.O

SPYRIDON DIMOTSANTOS

